Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April

Rhea-AI Summary

Alaunos Therapeutics (Nasdaq: TCRT), a prominent T-cell receptor cell therapy company, announced its participation in two upcoming investor conferences. The first is Cantor's The Future of Oncology Virtual Symposium on April 4, 2023, featuring fireside chats and one-on-one meetings. The second is the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, which will include a company presentation and one-on-one meetings. A live webcast of the Needham presentation will be available on Alaunos' website for 90 days post-event. Alaunos is advancing TCR therapies for solid tumors and collaborates with the National Cancer Institute.

HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.

Cantor's The Future of Oncology Virtual Symposium
Date: Tuesday, April 4, 2023
Format: Fireside Chat and 1x1 Meetings
Location: Virtual

22nd Annual Needham Virtual Healthcare Conference
Date: Monday, April 17, 2023
Format: Company Presentation and 1x1 Meetings
Location: Virtual

A live webcast of the Needham presentation will be accessible on the Company’s website in the Investors section under Events & Presentations at www.alaunos.com. A replay of the webcast will be available on the Alaunos website for approximately 90 days following the presentation.

About Alaunos Therapeutics
Alaunos Therapeutics is a leader in the science of T-cell receptor cell therapy working to revolutionize solid cancer treatment and outcomes. The clinical-stage company’s TCR T-cell therapy (TCR-T) is one of the most advanced TCR programs targeting driver mutations in solid tumors with an ongoing Phase 1/2 trial of its TCR-T product candidates across six solid cancers. Alaunos is powered by two proprietary platforms: its elegantly efficient non-viral Sleeping Beauty cell engineering platform; and its hunTR^® discovery platform, which is expanding its industry-leading library of TCRs against high-frequency driver mutations. Alaunos is a part of an ongoing collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), working to advance the science of TCR therapy. For more information, visit www.alaunos.com.

Investor Relations Contact:
Alex Lobo
Stern Investor Relations
alex.lobo@sternir.com

Media Contact:
Heather Anderson
6 Degrees PR
handerson@6degreespr.com

FAQ

What investor conferences is Alaunos Therapeutics participating in April 2023?

Alaunos Therapeutics is participating in Cantor's The Future of Oncology Virtual Symposium on April 4, 2023, and the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023.

Where can I watch the Alaunos Therapeutics webcast for the Needham Conference?

The live webcast of the Alaunos Therapeutics presentation at the Needham Conference can be accessed on the company's website under the Investors section.

What is the focus of Alaunos Therapeutics' TCR therapies?

Alaunos Therapeutics focuses on T-cell receptor (TCR) therapies aimed at treating solid tumors.

How long will the Alaunos webcast be available after the Needham Conference?

The webcast of the Alaunos Therapeutics presentation will be available for approximately 90 days following the Needham Conference.

What are the key features of Alaunos Therapeutics' TCR programs?

Alaunos Therapeutics' TCR programs are advanced in targeting driver mutations in solid tumors and involve a Phase 1/2 trial across six solid cancers.